BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Limagrain Takes A Commercial License To CELLECTIS SA' I-Scei Meganuclease Technology For Use In Plants


6/4/2009 12:18:19 PM

Parc Biocitech, Romainville - Chappes, June 2, 2009 - Cellectis S.A. (Alternext: ALCLS), a biotechnology company specialized in genome engineering, and Limagrain, an international cooperative group, announced today the signature of a non-exclusive license agreement on the use of the I-SceI meganuclease in plants. Following a successful research program under an April 2003 agreement between the parties, Limagrain exercised its option for a commercial license to use the Cellectis technology for the development of its agricultural products.

“We are happy to continue the collaboration with Limagrain into commercial development. By exercising its option for a license, Limagrain further substantiates our position in agricultural biotechnology, a market estimated at more than ten billion dollars with an annual growth rate in the order of fifteen percent (15%) and where our rational genome engineering technology brings an important competitive advantage. This commercial license taken by Limagrain brings us closer to having agricultural products based on our technologies on the market”, said André Choulika, CEO of Cellectis.

“This technology offers the possibility to create targeted insertions that allow the development of traits of interest to both the farmer and the consumer. It confirms Limagrain’s commitment to continue to invest in plant biotechnology. Biogemma, a plant biotechnology company in which we are a shareholder, is developing the technology and will be responsible for the production of the plants. Subsequently, the plants will be commercialized by Limagrain and other shareholders of Biogemma,” stated Daniel Chéron, CEO of Limagrain.

“This agreement is important because it complements our portfolio of technologies to develop genetically modified plants allowing the ability, among others, to assemble multiple traits of interest in a single plant. This is the result of years of extensive and efficient scientific collaboration. It opens the doors to new development opportunities,” said Pascual Perez, CEO of Biogemma.

About Cellectis S.A.

Cellectis S.A. (www.cellectis.com) is a world leader in genome engineering and genome surgery. For further information about Cellectis, visit our website at www.cellectis.com.

About Groupe Limagrain

Limagrain is an international agricultural cooperative group, expert in the improvement of plants. It conducts its business within the framework of a global, sustainable vision of agriculture. Limagrain bases its development on two key components, innovation and the regulation of agricultural markets. The Group has strong competitive positions: No. 1 seeds company in Europe and No. 4 in the world through Vilmorin & Cie, European leader for functional flours through Limagrain Céréales Ingrédients and 2nd largest French industrial baker through Jacquet. For further information about Limagrain, visit our website at www.limagrain.com

Disclaimer

This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavourable developments in connection with these and other risks and uncertainties described, in particular, in the Company’s prospectus prepared in connection with its IPO and on which the French Autorité des marchés financiers (“AMF”) granted its visa n° 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES